(2S)-2-(1-isocyanatocyclohexyl)thiolane 1,1-dioxide | 1220981-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: (2S)-2-(1-isocyanatocyclohexyl)thiolane 1,1-dioxide
• CAS: 1220981-60-1
• 化学式: C₁₁H₁₇NO₃S
• 分子量: 243.327
• InChiKey: WJSSGYQLZWYOSL-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  72
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,2S,5S)-methyl 3-((S)-2-amino-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride 、 (2S)-2-(1-isocyanatocyclohexyl)thiolane 1,1-dioxide 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl (1R,5S)-3-[3,3-dimethyl-1-oxo-2(S)-[[[[1-(tetrahydro-1,1-dioxido-2(S)-thienyl)cyclohexyl]amino]carbonyl]amino]butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxylate
  参考文献：
  名称：

  Cyclic Sulfones as Novel P3-Caps for Hepatitis C Virus NS3/4A (HCV NS3/4A) Protease Inhibitors: Synthesis and Evaluation of Inhibitors with Improved Potency and Pharmacokinetic Profiles

  摘要：

  HCV infection affects more than 170 million people worldwide and many of those patients will reach the end stage complications of the disease which include hepatocarcinoma and liver failure. The success rate for treatment of patients infected with genotype-1 is about 40%. Therefore, novel treatments are needed to combat the infection. The HCV NS3 protease inhibitor Boceprevir (1) was reported by our research group and efforts continue for the discovery of more potent compounds with improved pharmacokinetic profiles. A new series of HCV NS3 protease inhibitors having a cyclic sulfone P3-cap have been discovered. Compounds 43 and 44 showed K-i* values in the single-digit nM range and their cellular potency was improved by 10-fold compared to 1. The pharmacokinetic profiles of 43 and 44 in rats and monkeys were also improved to achieve higher plasma levels after oral administration.

  DOI：

  10.1021/jm9016027
• 作为产物：
  描述：

  光气 、 1-(tetrahydro-1,1-dioxido-2(S)-thienyl)cyclohexylamine hydrochloride 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 以99%的产率得到(2S)-2-(1-isocyanatocyclohexyl)thiolane 1,1-dioxide
  参考文献：
  名称：

  Cyclic Sulfones as Novel P3-Caps for Hepatitis C Virus NS3/4A (HCV NS3/4A) Protease Inhibitors: Synthesis and Evaluation of Inhibitors with Improved Potency and Pharmacokinetic Profiles

  摘要：

  HCV infection affects more than 170 million people worldwide and many of those patients will reach the end stage complications of the disease which include hepatocarcinoma and liver failure. The success rate for treatment of patients infected with genotype-1 is about 40%. Therefore, novel treatments are needed to combat the infection. The HCV NS3 protease inhibitor Boceprevir (1) was reported by our research group and efforts continue for the discovery of more potent compounds with improved pharmacokinetic profiles. A new series of HCV NS3 protease inhibitors having a cyclic sulfone P3-cap have been discovered. Compounds 43 and 44 showed K-i* values in the single-digit nM range and their cellular potency was improved by 10-fold compared to 1. The pharmacokinetic profiles of 43 and 44 in rats and monkeys were also improved to achieve higher plasma levels after oral administration.

  DOI：

  10.1021/jm9016027

文献信息

• Cyclic Sulfones as Novel P3-Caps for Hepatitis C Virus NS3/4A (HCV NS3/4A) Protease Inhibitors: Synthesis and Evaluation of Inhibitors with Improved Potency and Pharmacokinetic Profiles
  作者：Francisco Velázquez、Mousumi Sannigrahi、Frank Bennett、Raymond G. Lovey、Ashok Arasappan、Stéphane Bogen、Latha Nair、Srikanth Venkatraman、Melissa Blackman、Siska Hendrata、Yuhua Huang、Regina Huelgas、Patrick Pinto、Kuo-Chi Cheng、Xiao Tong、Andrew T. McPhail、F. George Njoroge

  DOI：10.1021/jm9016027

  日期：2010.4.22

  HCV infection affects more than 170 million people worldwide and many of those patients will reach the end stage complications of the disease which include hepatocarcinoma and liver failure. The success rate for treatment of patients infected with genotype-1 is about 40%. Therefore, novel treatments are needed to combat the infection. The HCV NS3 protease inhibitor Boceprevir (1) was reported by our research group and efforts continue for the discovery of more potent compounds with improved pharmacokinetic profiles. A new series of HCV NS3 protease inhibitors having a cyclic sulfone P3-cap have been discovered. Compounds 43 and 44 showed K-i* values in the single-digit nM range and their cellular potency was improved by 10-fold compared to 1. The pharmacokinetic profiles of 43 and 44 in rats and monkeys were also improved to achieve higher plasma levels after oral administration.